Your browser doesn't support javascript.
loading
Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials.
Whitley, Jill; Zwolinski, Christopher; Denis, Christian; Maughan, Maureen; Hayles, Leonie; Clarke, David; Snare, Meghan; Liao, Hong; Chiou, Sean; Marmura, Tina; Zoeller, Holly; Hudson, Ben; Peart, John; Johnson, Monica; Karlsson, Amelia; Wang, Yunfei; Nagle, Cynthia; Harris, Cherell; Tonkin, Daniel; Fraser, Stephanie; Capiz, Lieza; Zeno, Christina L; Meli, Yvonne; Martik, Diana; Ozaki, Daniel A; Caparoni, Amy; Dickens, Jason E; Weissman, Drew; Saunders, Kevin O; Haynes, Barton F; Sempowski, Gregory D; Denny, Thomas N; Johnson, Matthew R.
Afiliação
  • Whitley J; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Zwolinski C; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Denis C; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Maughan M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Hayles L; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Clarke D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Snare M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Liao H; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Chiou S; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Marmura T; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Zoeller H; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Hudson B; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Peart J; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Johnson M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Karlsson A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Wang Y; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Nagle C; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Harris C; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Tonkin D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Fraser S; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Capiz L; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Zeno CL; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Meli Y; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Martik D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Ozaki DA; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Caparoni A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Dickens JE; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Weissman D; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Saunders KO; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Sempowski GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
  • Denny TN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina. Electronic address: thomas.denny@duke.edu.
  • Johnson MR; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
Transl Res ; 242: 38-55, 2022 04.
Article em En | MEDLINE | ID: mdl-34871810
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Revista: Transl Res Assunto da revista: MEDICINA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Revista: Transl Res Assunto da revista: MEDICINA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Ano de publicação: 2022 Tipo de documento: Article